Aerie Pharmaceuticals (AERI) Earns Daily Media Impact Score of 0.24
News stories about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.4563970314267 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- Aerie Pharmaceuticals Inc (AERI) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Prescribed Reading: FDA approval spree, tax reform, deals pick up (biopharmadive.com)
- Is Aerie Pharmaceuticals Inc (NASDAQ:AERI) A Financially Sound Company? (finance.yahoo.com)
- Aerie Pharmaceuticals, Inc. (AERI) : Investors watching Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) – Volatile Stock to Watch – Alpha Beta Stock (alphabetastock.com)
A number of equities analysts recently commented on AERI shares. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Mizuho started coverage on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price target on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Finally, Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $72.00.
Aerie Pharmaceuticals (NASDAQ:AERI) traded up $1.45 during mid-day trading on Friday, reaching $60.70. 284,415 shares of the company’s stock traded hands, compared to its average volume of 361,837. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 52-week low of $35.50 and a 52-week high of $66.60. The company has a market cap of $2,280.00, a price-to-earnings ratio of -18.12 and a beta of 1.11.
ILLEGAL ACTIVITY NOTICE: This report was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2017/12/24/aerie-pharmaceuticals-aeri-earns-daily-media-impact-score-of-0-24.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.